Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study
| Autor: | Luan-Yin Chang, Chou-Cheng Lai, Chia-Yuan Chang, Li-Min Huang, Miao-Chiu Hung, Keh-Gong Wu, Ching-Yi Cho, Chun-Yi Lu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Quadrivalent Inactivated Influenza Vaccine
Trivalent influenza vaccine Adolescent Taiwan Antibodies Viral Group B 03 medical and health sciences 0302 clinical medicine Immunogenicity Vaccine 030225 pediatrics Influenza Human Medicine Humans 030212 general & internal medicine Seroconversion Adverse effect Child Hemagglutination assay General Veterinary General Immunology and Microbiology business.industry Immunogenicity Public Health Environmental and Occupational Health Hemagglutination Inhibition Tests Virology Healthy Volunteers Vaccination Influenza B virus Infectious Diseases Vaccines Inactivated Influenza Vaccines Child Preschool Molecular Medicine business |
| Zdroj: | Vaccine. 38(22) |
| ISSN: | 1873-2518 |
| Popis: | Background Quadrivalent influenza vaccines are particularly valuable during seasons in which a mismatch occurs between the predicted influenza B lineage for the trivalent influenza vaccine and the circulating strain. This study evaluated the immunogenicity and safety of a quadrivalent inactivated influenza vaccine AdimFlu-S manufactured in Taiwan for the 2016–2017 influenza season in healthy children. Methods A total of 174 healthy children aged 3 to 17 years old were separated into 3 groups (Group A: 3–8 years old, vaccine naive; Group B: 3–8 years old, vaccine non-naive; Group C: 9–17 years old, any vaccine status). Sera was collected pre and post vaccination for each participant. A hemagglutination inhibition (HAI) assay was utilized to calculate geometric mean titer (GMT), seroprotection rate, and seroconversion rate. Results All enrolled participants completed the study. For the four vaccine strains four weeks after the last vaccination, geometric mean titer ratios (GMTRs) were between 2.9 and 20.9, seroconversion rates were between 42.9% and 90.9%, and seroprotection rates were all above 96.4%. This achieved all immunogenicity endpoints and fulfilled the criteria of the European Medical Agency’s Committee for Medicinal Products for Human Use (CHMP). No serious adverse events (AEs) were reported during the follow-up period of 6 months. Conclusion This quadrivalent influenza vaccine is demonstrated to be well tolerated and displays robust immunogenicity for each influenza strain. This could potentially improve protection against the antigenically distinct B/Yamagata and B/Victoria lineages. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect